In your interest.
Online Personal Finance Magazine
No beating about the bush.
We are replacing two stocks in our long-term Stockgrader list. Here is a review
Pharma continues to be in the limelight and is poised for more of it, thanks to Ranbaxy’s blockbuster deal with Daiichi of Japan. The market thinks that this takeover has set the stage for smaller companies, particularly those operating in contract research and the manufacturing arena, to be targets of...